Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

Assessing Darunavir/Ritonavir—Based Therapy in a Racially Diverse Population: 48-Week Outcomes From GRACE

(2016) Kimberly Y. Smith et al.   JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

(2013) Joel E. Gallant et al.   JOURNAL OF INFECTIOUS DISEASES

Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection

(2013) Bhavik M. Shah et al.   PHARMACOTHERAPY

Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340,In Vitro

(2012) Eve-Irene Lepist et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN

(2012) Denes Banhegyi et al.   CURRENT HIV RESEARCH

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

(2012) C Orkin et al.   HIV MEDICINE

Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naïve HIV patients

(2012) A Buscher et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Antiretroviral Treatment of Adult HIV Infection

(2012) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era

(2012) Gaetana Sterrantino et al.   Patient Preference and Adherence

Spillover adherence effects of fixed-dose combination HIV therapy

(2012) Teresa Kauf et al.   Patient Preference and Adherence

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

(2011) Pedro Cahn et al.   AIDS

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

(2011) Richard Elion et al.   AIDS

Ritonavir-boosted protease inhibitors in HIV therapy

(2011) Mark W. Hull et al.   ANNALS OF MEDICINE

Factors Associated with Complete Adherence to HIV Combination Antiretroviral Therapy

(2011) Timothy Juday et al.   HIV CLINICAL TRIALS

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

(2011) Akil Jackson et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults

(2010) Katherine Samaras et al.   AIDS

Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients

(2010) Rob Ter Heine et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Multiple Peaking Phenomena in Pharmacokinetic Disposition

(2010) Neal M. Davies et al.   CLINICAL PHARMACOKINETICS

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

(2010) Lianhong Xu et al.   ACS Medicinal Chemistry Letters

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

(2009) Anthony M Mills et al.   AIDS

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

(2009) A A Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy Subjects

(2009) M. Vermeir et al.   DRUG METABOLISM AND DISPOSITION

Induction Effects of Ritonavir: Implications for Drug Interactions

(2008) Michelle M Foisy et al.   ANNALS OF PHARMACOTHERAPY